To include your compound in the COVID-19 Resource Center, submit it here.

Eylea clears first Phase III hurdle in diabetic retinopathy subset

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said Eylea aflibercept met the first of two primary endpoints in the Phase III PANORAMA trial to treat non-proliferative diabetic retinopathy without diabetic macular edema (DME). The

Read the full 318 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE